Abstract
Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
Keywords: PTP1B, TCPTP, p-Nitro phenyl phosphate, Type II diabetes, Obesity.
Mini-Reviews in Medicinal Chemistry
Title:Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening
Volume: 13 Issue: 11
Author(s): M. V.V.V. Sekhar Reddy, Chakshusmathi Ghadiyaram, Sunil Kumar Panigrahi, Subramanya Hosahalli and Lakshmi Narasu Mangamoori
Affiliation:
Keywords: PTP1B, TCPTP, p-Nitro phenyl phosphate, Type II diabetes, Obesity.
Abstract: Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
Export Options
About this article
Cite this article as:
Reddy V.V.V. Sekhar M., Ghadiyaram Chakshusmathi, Panigrahi Kumar Sunil, Hosahalli Subramanya and Mangamoori Narasu Lakshmi, Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening, Mini-Reviews in Medicinal Chemistry 2013; 13 (11) . https://dx.doi.org/10.2174/1389557511313110006
DOI https://dx.doi.org/10.2174/1389557511313110006 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier
Current Cancer Drug Targets EDITORIAL [Hot Topic Recognition of Functional Roles of Free Radicals Guest Editor: István Bokkon]
Current Neuropharmacology Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Perception or Reality of Body Weight: Which Matters the Most to Adolescents’ Emotional Well-being?
Current Psychiatry Reviews Are Cerebrovascular White Matter Lesions an Early Sign of Vascular Cognitive Impairment and Vascular Dementia?
Vascular Disease Prevention (Discontinued) Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Estrogen: Roles in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Current Neurovascular Research Transition of Growth Hormone Treatment: Adolescence to Adulthood
Current Pediatric Reviews RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases
Current Pharmaceutical Design Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Editorial [Hot topic:Expression and Refolding Technologies for Production of Recombinant Proteins (Guest Editors: Tsutomu Arakawa and Kouhei Tsumoto)]
Current Pharmaceutical Biotechnology Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Current Pharmaceutical Design Alternative Medicine Safety: Agaricus blazei and Propolis
Combinatorial Chemistry & High Throughput Screening Literature Review on Diabetes Internet-based Spanish-Language Information
Current Diabetes Reviews Ketamine-Induced Neurotoxicity and Changes in Gene Expression in the Developing Rat Brain
Current Neuropharmacology Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?
Current Drug Targets Protrhombotic Effects of Contraceptives
Current Pharmaceutical Design Role of Thyroid Hormones in Insulin Resistance and Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) MRI findings and renal function in patients on lithium therapy
Current Drug Safety